FindTrial
Sign In

The impact of the dexamethasone in different administration routes on effectiveness of prevent complications of epidural analgesia

The impact of the dexamethasone in different administration routes on effectiveness of prevent complications of epidural analgesia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17013101
Enrollment
Unknown
Registered
2017-10-25
Start date
2017-10-30
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower extremity surgery

Interventions

A:None
B:dexamethasone 5mg
C:The vein gave the drug dexamethasone 5mg

Sponsors

Suzhou Science and Technology Town Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. ASA rating level 1 or level 2; 2. Normal liver and kidney function; 3. Normal coagulation function; 4. Elective surgery patients of lower abdomen or lower extremities without?other major disease.;Inclusion criteria: 1. ASA rating level 1 or level 2; 2. Normal liver and kidney function; 3. Normal coagulation function; 4. Elective surgery patients of lower abdomen or lower extremities without?other major disease.;Inclusion criteria: 1. ASA rating level 1 or level 2; 2. Normal liver and kidney function; 3. Normal coagulation function; 4. Elective surgery patients of lower abdomen or lower extremities without?other major disease.;Inclusion criteria: 1. ASA rating level 1 or level 2; 2. Normal liver and kidney function; 3. Normal coagulation function; 4. Elective surgery patients of lower abdomen or lower extremities without?other major disease.;Inclusion criteria: 1. ASA rating level 1 or level 2; 2. Normal liver and kidney function; 3. Normal coagulation function; 4. Elective surgery patients of lower abdomen or lower extremities without?other major disease.

Exclusion criteria

Exclusion criteria: Abnormal blood clotting time, local puncture and systemic infection;Exclusion criteria: Abnormal blood clotting time, local puncture and systemic infection;Exclusion criteria: Abnormal blood clotting time, local puncture and systemic infection;Exclusion criteria: Abnormal blood clotting time, local puncture and systemic infection;Exclusion criteria: Abnormal blood clotting time, local puncture and systemic infection

Design outcomes

Primary

MeasureTime frame
Skin itching, nausea, vomiting and chills;—

Countries

China

Contacts

Public ContactXia Yanzhi;Xia Yanzhi;Xia Yanzhi;Xia Yanzhi;Xia Yanzhi ;;;;

Suzhou Science and Technology Town Hospital;Suzhou Science and Technology Town Hospital;Suzhou Science and Technology Town Hospital;Suzhou Science and Technology Town Hospital;Suzhou Science and Technology Town Hospital

847576705@qq.com;847576705@qq.com;847576705@qq.com;847576705@qq.com;847576705@qq.com+86 13770063210;+86 13770063210;+86 13770063210;+86 13770063210;+86 13770063210

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026